For questions regarding claiming CME Credit, please refer to our FAQ section.


Novel Therapeutic Pathways in the Secondary Prevention  of Atherothrombotic Events in AMI

Program Overview:

Specific populations may be at particular risk for either, and the issues of appropriate antiplatelet regimens for various patients remain a concern. This webcast focuses on chronic antiplatelet therapy in high-risk patients, especially post-MI patients or those with PAD, and in particular the use of protease-activated receptor antagonists (PRA-1 antagonists).


Click Here to access this CME Program   
Release Date:
June 9th, 2015

Expiration Date:
December 9th, 2015 

Estimated Time:
1 hour    
 
 
MATRIX and REGULATE PCI CME Webcast

Program Overview:

The MATRIX and REGULATE-PCI trials examine 2 of the major bleeding avoidance strategies in patients with acute coronary syndrome (ACS): access-site location and choice of antithrombin agent.This webcast will include data presentation, panel discussion, and audience question and answer opportunities.


Click Here to access this CME Program   
Release Date:
June 8th, 2015

Expiration Date:
December 8th, 2015 

Estimated Time:
1 hour    


PEGASUS, TOTAL and DANAMI3-PRIMULTI

Program Overview:

Patients with STEMI undergoing primary PCI continue to have worse outcomes and higher mortality, bleeding, stent thrombosis, and secondary cardiovascular events. Patterns and controversies unique to primary PCI for STEMI, such as whether radial access benefits patients and what the roles should be for complete revascularization and thrombus aspiration, are evolving. Three trials presented at ACC 2015, combining over 30,000 patients, provide insight into some of these issues. The TOTAL study addresses routine thrombus aspiration, while DANAMI3-PRIMULTI looks at multivessel revascularization and delayed stenting. New information on long-term use of dual antiplatelet therapy comes from PEGASUS-TIMI 54, which evaluated the use of ticagrelor with aspirin for secondary prevention in high-risk patients 1 to 3 years after MI. This webcast will summarize the data, answer audience questions, and provide context through panel discussion on the TOTAL, PEGASUS-TIMI 54, and DANAMI3-PRIMULTI studies.


Click Here to access this CME Program   
Release Date:
June 8th, 2015

Expiration Date:
December 8th, 2015 

Estimated Time:
1 hour